{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T01:14:05Z","timestamp":1774574045543,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Eribulin is an inhibitor of microtubule dynamics. It is not as highly protein bound as the taxanes and is less vulnerable to extrusion by P-glycoprotein in the blood\u2013brain barrier (BBB). These features predict that eribulin could play an active role in managing brain tumors. Indeed, the small amount of published clinical data indicates eribulin may have some efficacy against breast cancer brain metastases. To better understand the potential of eribulin for treating brain tumors, we performed an intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in cancer patients undergoing tumor resection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>After tumor removal, two microdialysis catheters were inserted into peritumoral brain tissue. Approximately 24\u00a0h after surgery, a single dose of eribulin 1.4\u00a0mg\/m<jats:sup>2<\/jats:sup> was administered intravenously. Dialysate samples were collected continuously for 72\u00a0h, with plasma samples collected in parallel. Eribulin concentrations were analyzed by tandem mass spectrometry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Dialysate samples from 12 intracerebral microdialysis catheters placed in 7 study participants were included in the analysis. A statistically significant difference was observed between eribulin concentrations in brain tissue where BBB was disrupted versus intact, with a difference in mean maximum concentrations on log<jats:sub>2<\/jats:sub> scale of 3.37 (std err\u2009=\u20090.59, <jats:italic>p<\/jats:italic>-value\u2009=\u20090.005). Nonetheless, overall brain to plasma ratios of eribulin only ranged from 0.13 to 1.99%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although we could detect higher concentrations of eribulin in brain tissue where BBB was disrupted, intracerebral eribulin levels were not sufficient to predict eribulin would have consistent clinically meaningful activity against tumors in the brain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>ClinicalTrials.gov Identifier<\/jats:title>\n                <jats:p>NCT02338037 (January 9, 2015).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00280-024-04711-2","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T10:02:40Z","timestamp":1729245760000},"page":"807-813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors"],"prefix":"10.1007","volume":"94","author":[{"given":"Zeynep","family":"Eroglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Synold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behnam","family":"Badie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnab","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Kilpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzette","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Portnow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"4711_CR1","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.2217\/fon-2018-0936","volume":"15","author":"J O'Shaughnessy","year":"2019","unstructured":"O\u2019Shaughnessy J, Kaklamani V, Kalinsky K (2019) Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. Future Oncol 15:1641\u20131653. https:\/\/doi.org\/10.2217\/fon-2018-0936","journal-title":"Future Oncol"},{"key":"4711_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2011.03.002","volume":"81","author":"U Swami","year":"2012","unstructured":"Swami U, Chaudhary I, Ghalib MH, Goel S (2012) Eribulin \u2013 a review of preclinical and clinical studies. Crit Rev Oncol Hematol 81:163\u2013184. https:\/\/doi.org\/10.1016\/j.critrevonc.2011.03.002","journal-title":"Crit Rev Oncol Hematol"},{"key":"4711_CR3","unstructured":"Zheng W, Seletsky B, Palme M, Habgood G, Singer L, Dipietro L. (2003). Structure-activity relationships of synthetic halicondrin B analog E7389: in vitro susceptibility to PgP-mediated drug efflux. Proc Am Assoc Cancer Res 7: Abst 2751."},{"key":"4711_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00280-017-3369-7","volume":"80","author":"M Sugawara","year":"2017","unstructured":"Sugawara M, Condon K, Liang E et al (2017) Eribulin shows high concentration and long retention in xenograft tumor tissues. Cancer Chemother Pharmacol 80:377\u2013384. https:\/\/doi.org\/10.1007\/s00280-017-3369-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"4711_CR5","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1111\/cas.14067","volume":"110","author":"M Takahashi","year":"2019","unstructured":"Takahashi M, Miki S, Fujimoto K et al (2019) Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Sci 110:2247\u20132257. https:\/\/doi.org\/10.1111\/cas.14067","journal-title":"Cancer Sci"},{"key":"4711_CR6","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1517\/17425255.2010.523420","volume":"6","author":"J Blakeley","year":"2010","unstructured":"Blakeley J, Portnow J (2010) Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development. Expert Opin Drug Metab Toxicol 6:1477\u20131491. https:\/\/doi.org\/10.1517\/17425255.2010.523420","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4711_CR7","unstructured":"Eroglu Z PJ, Sacramento A, Garcia E, Raubitschek A, Synold T. (2013). A microdialysis study to assess intracerebral concentrations of irinotecan and eribulin with or without iRGD in an orthotopic glioma rat model. Neuro Oncol 15: iii37-iii61."},{"key":"4711_CR8","first-page":"1013","volume":"61","author":"MJ Towle","year":"2001","unstructured":"Towle MJ, Salvato KA, Budrow J et al (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61:1013\u20131021","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"4711_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000489066","volume":"94","author":"G Catania","year":"2018","unstructured":"Catania G, Malaguti P, Gasparro S, Cognetti F, Vidiri A, Fabi A (2018) Activity of eribulin mesylate in brain metastasis from breast cancer: a stone in a pond? Oncology 94(Suppl 1):29\u201333. https:\/\/doi.org\/10.1159\/000489066","journal-title":"Oncology"},{"key":"4711_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4137\/BCBCR.S21176","volume":"9","author":"AY Chang","year":"2015","unstructured":"Chang AY, Ying XX (2015) Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: a Case Series. Breast Cancer (Auckl) 9:19\u201324. https:\/\/doi.org\/10.4137\/BCBCR.S21176","journal-title":"Breast Cancer (Auckl)"},{"key":"4711_CR11","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.asjsur.2020.05.002","volume":"43","author":"SU Jung","year":"2020","unstructured":"Jung SU, Jeon CW, Choi JH (2020) Long-term survival with eribulin monotherapy after whole brain radiation therapy in a patient with brain metastasis from breast cancer. Asian J Surg 43:1008\u20131009. https:\/\/doi.org\/10.1016\/j.asjsur.2020.05.002","journal-title":"Asian J Surg"},{"key":"4711_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1186\/1756-0500-6-541","volume":"6","author":"H Matsuoka","year":"2013","unstructured":"Matsuoka H, Tsurutani J, Tanizaki J et al (2013) Regression of brain metastases from breast cancer with eribulin: a case report. BMC Res Notes 6:541. https:\/\/doi.org\/10.1186\/1756-0500-6-541","journal-title":"BMC Res Notes"},{"key":"4711_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/537183","volume":"2012","author":"C Nieder","year":"2012","unstructured":"Nieder C, Aandahl G, Dalhaug A (2012) A case of brain metastases from breast cancer treated with whole-brain radiotherapy and eribulin mesylate. Case Rep Oncol Med 2012:537183. https:\/\/doi.org\/10.1155\/2012\/537183","journal-title":"Case Rep Oncol Med"},{"key":"4711_CR14","doi-asserted-by":"publisher","first-page":"175883591989575","DOI":"10.1177\/1758835919895755","volume":"11","author":"V Adamo","year":"2019","unstructured":"Adamo V, Ricciardi GRR, Giuffrida D et al (2019) Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study. Ther Adv Med Oncol 11:1758835919895755. https:\/\/doi.org\/10.1177\/1758835919895755","journal-title":"Ther Adv Med Oncol"},{"key":"4711_CR15","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.2217\/fon-2021-0300","volume":"17","author":"A Fabi","year":"2021","unstructured":"Fabi A, Terrenato I, Vidiri A et al (2021) Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial. Future Oncol 17:3445\u20133456. https:\/\/doi.org\/10.2217\/fon-2021-0300","journal-title":"Future Oncol"},{"key":"4711_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061272","author":"R Sabatier","year":"2021","unstructured":"Sabatier R, Martin J, Vicier C et al (2021) Eribulin efficacy on brain metastases in heavily pretreated patients with metastatic breast cancer. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10061272","journal-title":"J Clin Med"},{"key":"4711_CR17","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00280-015-2868-7","volume":"76","author":"RJ Morgan","year":"2015","unstructured":"Morgan RJ, Synold TW, Longmate JA et al (2015) Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemother Pharmacol 76:897\u2013907. https:\/\/doi.org\/10.1007\/s00280-015-2868-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"4711_CR18","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1158\/1078-0432.CCR-08-2429","volume":"15","author":"S Goel","year":"2009","unstructured":"Goel S, Mita AC, Mita M et al (2009) A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 15:4207\u20134212. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2429","journal-title":"Clin Cancer Res"},{"key":"4711_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00280-019-03877-4","volume":"84","author":"S Goel","year":"2019","unstructured":"Goel S, Swami U, Kumar K et al (2019) A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer. Cancer Chemother Pharmacol 84:567\u2013578. https:\/\/doi.org\/10.1007\/s00280-019-03877-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"4711_CR20","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00280-015-2878-5","volume":"76","author":"AR Tan","year":"2015","unstructured":"Tan AR, Sarantopoulos J, Lee L et al (2015) Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function. Cancer Chemother Pharmacol 76:1051\u20131061. https:\/\/doi.org\/10.1007\/s00280-015-2878-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"4711_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2165\/00003088-200241100-00001","volume":"41","author":"EC de Lange","year":"2002","unstructured":"de Lange EC, Danhof M (2002) Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 41:691\u2013703. https:\/\/doi.org\/10.2165\/00003088-200241100-00001","journal-title":"Clin Pharmacokinet"},{"key":"4711_CR22","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","volume":"16","author":"NU Lin","year":"2015","unstructured":"Lin NU, Lee EQ, Aoyama H et al (2015) Response assessment criteria for brain metastases: proposalfrom the RANO group. Lancet Oncol 16:e270-278. https:\/\/doi.org\/10.1016\/S1470-2045(15)70057-4","journal-title":"Lancet Oncol"},{"key":"4711_CR23","doi-asserted-by":"publisher","first-page":"7092","DOI":"10.1158\/1078-0432.CCR-09-1349","volume":"15","author":"J Portnow","year":"2009","unstructured":"Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW (2009) The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res 15:7092\u20137098. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1349","journal-title":"Clin Cancer Res"},{"key":"4711_CR24","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.ejca.2013.01.001","volume":"49","author":"J Portnow","year":"2013","unstructured":"Portnow J, Badie B, Markel S et al (2013) A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl\/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas. Eur J Cancer 49:1634\u20131640. https:\/\/doi.org\/10.1016\/j.ejca.2013.01.001","journal-title":"Eur J Cancer"},{"key":"4711_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis CD, Ferraro GB, Jain RK (2020) The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer 20:26\u201341. https:\/\/doi.org\/10.1038\/s41568-019-0205-x","journal-title":"Nat Rev Cancer"},{"key":"4711_CR26","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1124\/dmd.108.024745","volume":"37","author":"S Syvanen","year":"2009","unstructured":"Syvanen S, Lindhe O, Palner M et al (2009) Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 37:635\u2013643. https:\/\/doi.org\/10.1124\/dmd.108.024745","journal-title":"Drug Metab Dispos"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04711-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04711-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04711-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:03:02Z","timestamp":1731974582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04711-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["4711"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04711-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The clinical protocol for this non-therapeutic study was approved by the City of Hope Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}